ESMO 2022 Conference Coverage
ESMO 2022 on the 4-Factor Model to Predict Response and Survival Benefit With Durvalumab in Previously Treated Metastatic Urinary Tract Carcinoma
By
ESMO 2022 Conference Coverage
FEATURING
Guru Sonpavde
By
ESMO 2022 Conference Coverage
FEATURING
Guru Sonpavde
Comments 0
Login to view comments.
Click here to Login
